Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus rating of “Moderate Buy” by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.67.

ATRA has been the topic of a number of research analyst reports. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price objective for the company from $25.00 to $18.00 in a report on Friday, August 16th. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Canaccord Genuity Group lifted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

Institutional Trading of Atara Biotherapeutics

A number of large investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. State Street Corp grew its holdings in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares during the period. Vestal Point Capital LP raised its position in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after acquiring an additional 12,677 shares in the last quarter. FMR LLC lifted its holdings in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth $79,000. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Trading Down 6.8 %

Shares of ATRA stock opened at $10.95 on Friday. Atara Biotherapeutics has a twelve month low of $6.50 and a twelve month high of $39.50. The stock has a market cap of $63.07 million, a P/E ratio of -0.42 and a beta of 0.55. The stock has a 50 day moving average of $10.49 and a 200 day moving average of $9.78.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the previous year, the firm posted ($16.50) EPS. On average, research analysts predict that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.